mitochondrial ribosomal protein S21 pseudogene 6Genealiases: []
Q-omics provides the consensus-scored MRPS21P6 profile across patient tissues and cancer cell-line models. MRPS21P6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MRPS21P6 is differentially expressed in 6, with the highest sampling consensus in UCEC. Additionally, MRPS21P6 RNA expression shows 6,423 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, UCEC, and STAD as cancer lineages where MRPS21P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS21P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS21P6 survival associations across molecular data types. MRPS21P6 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS21P6 RNA expression–survival associations across cancer types. High MRPS21P6 expression shows unfavorable associations in KIRC, LIHC, KIRP and READ, but favorable associations in MESO and LGG. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify MESO as the clearest survival context for MRPS21P6 RNA expression.
This table summarizes MRPS21P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRPS21P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS21P6 shows lower tumor expression in UCEC and KICH and higher tumor expression in BRCA, LUAD, HNSC and STAD. The UCEC box plot shows higher MRPS21P6 RNA expression in normal versus tumor tissue (log2 FC = −0.600, t-test p = .002).
This table shows molecular features associated with MRPS21P6 in patient tissues and cancer cell lines. In patient samples, MRPS21P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
